---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-006602"
form_type: "8-K"
ticker: "RYTM"
cik: "0001649904"
company_name: "RHYTHM PHARMACEUTICALS, INC."
filed_at: "2025-05-07T23:59:59+00:00"
generated_at: "2026-05-22T08:19:23.801463+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Rhythm Q1 product rev $37.7M; Phase 3 HO trial meets endpoint with -19.8% BMI reduction

## Summary
- Net product revenue $37.7M, up from $26.0M YoY; U.S. $24.5M, ex-U.S. $13.2M.
- Net loss $50.8M ($0.81 per share) vs $141.4M ($2.35) YoY; R&D down due to prior-year acquisition cost.
- Phase 3 TRANSCEND trial met primary endpoint: -19.8% placebo-adjusted BMI reduction at 52 weeks (p<0.0001); no new safety signals.
- Cash and investments $314.5M as of March 31, 2025; cash runway into 2027.
- Fiscal 2025 Non-GAAP operating expense guidance $285M-$315M; regulatory submissions for HO in Q3 2025.

## SEC filing metadata
- accession: 0001558370-25-006602
- form_type: 8-K
- ticker: RYTM
- cik: 0001649904
- company_name: RHYTHM PHARMACEUTICALS, INC.
- filed_at: 2025-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649904/000155837025006602/0001558370-25-006602-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649904/000155837025006602/rytm-20250507x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-006602
- JSON: https://secwatch.observer/filing/0001558370-25-006602.json
- Plain text: https://secwatch.observer/filing/0001558370-25-006602.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.